Domestic lenalidomide is a new generation of immunomodulatory antitumor drugs. The medical insurance price of domestic lenalidomide is 10mg×2 1 tablet/bottle, and the drug store price is 18 186 yuan. 25mg×2 1 tablet/bottle, drugstore price: 23 14 1 yuan. The reimbursement rate is as high as 75%. Such a high reimbursement rate has greatly reduced the huge medical expenses for cancer patients. Lenalidomide is a new generation of immunomodulatory antineoplastic drugs developed by Celgene Company in the United States. It was first approved by FDA in 2005 for the treatment of myelodysplastic syndrome (MDS), and was approved in 2006 for the second-line treatment of multiple myeloma in combination with dexamethasone. Later, it was approved by FDA for the treatment of mantle cell lymphoma. From 2065438 to 2006, nadamide was approved to be used in the first-line treatment of multiple myeloma in combination with dexamethasone. In June 2007, it was approved by the European Union for multiple myeloma. 20 13 was listed in China under the trade name of "Ruifumei" in June. At present, lenalidomide is the first-line drug recommended by the treatment guidelines for myelodysplastic syndrome and multiple myeloma.
20 17, 19 On July 9, Ministry of Human Resources and Social Security issued the Notice on Incorporating 36 Drugs into Class B of the National Drug List of Basic Medical Insurance, Work Injury Insurance and Maternity Insurance, and lenalidomide was among them. After domestic medical insurance (1 tablet 10mg is 866 yuan) and (1 tablet/25mg is 1. 99 yuan), the lenalidomide of these two specifications is 2 1 tablet and/kloc per box. In addition, according to the latest data of 20 19 Indian big hospital, lenalidomide has four different specifications in India, namely 5mg, 10mg, 15mg, 25mg, with 30 capsules per box. The prices of these four specifications are in 500 yuan, 1000 yuan and 65438 yuan respectively. Of course, the specific reimbursement expenses need to be accurately calculated in combination with the floating exchange rate.